UNSPSC 51263158: Carteolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H24N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4797W6I0T4, chemically known as 2(1h)-quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro- but more generally known as carteolol hydrochloride, which bears US NIH Compound Identifier 2583. European Medicines Agency schedules Carteolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13251MIG.

UNSPSC 51263158 Carteolol hydrochloride is a Commodity code that nominally describes a single pharmaceutical product—carteolol hydrochloride, a beta-blocker ophthalmic agent—but the recent state and local solicitations tagged under this code do not align with that scope. The most recent opportunity on record, Seminole County, Florida's IFB60459723LAS (posted June 30, 2026), solicits Naloxone and Safe Drug Deactivation Systems for community health initiatives, a product category entirely outside carteolol's pharmaceutical indication. The mismatch suggests either miscoding at the issuing body's end or a vendor-submitted code that does not reflect the actual procurement. Code activity appears limited, with no additional recent opportunities in the source to establish a pattern of state and local buying under the carteolol classification.

Seminole County represents the sole recent issuing body on record for this code. The IFB seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, with response due July 26, 2023—a date that has passed relative to the current date (October 20, 2026). Vendors were required to submit pricing, hold E-Verify compliance, carry workers' compensation and general liability coverage, and accept a three-month probationary termination clause. Pursuit of opportunities under this code is not advised given the apparent miscoding and the absence of carteolol-related recent solicitations.